Aspirin as Antiplatelet Therapy: Clinical Indications and Diagnoses
Aspirin is prescribed as an antiplatelet agent primarily for patients with atherosclerotic cardiovascular disease or those at high risk of thrombotic vascular events, suggesting diagnoses such as acute coronary syndromes (myocardial infarction, unstable angina), ischemic stroke or TIA, peripheral arterial disease, stable angina, or atrial fibrillation. 1
Primary Cardiovascular Indications
When a patient receives aspirin for antiplatelet therapy, the following diagnoses should be considered:
Acute Coronary Syndromes
- Acute myocardial infarction: Aspirin 160-325 mg loading dose reduces vascular death by 23% and non-fatal vascular events by 50% when started within 24 hours of symptom onset 1
- Unstable angina: Aspirin reduces myocardial infarction and death by approximately 50% across doses of 75-1300 mg daily 1
- Stable angina: Daily aspirin 75 mg reduces myocardial infarction or sudden death by 34% over extended follow-up 1
Cerebrovascular Disease
- Acute ischemic stroke: Aspirin 160-300 mg daily reduces early mortality and stroke recurrence 2
- Previous stroke or TIA: Aspirin reduces subsequent stroke risk, with effective doses as low as 50 mg daily 2
- Asymptomatic carotid stenosis: Aspirin is recommended for all patients with significant carotid disease 3
- Post-carotid endarterectomy: Aspirin 81-325 mg daily reduces perioperative stroke risk 4, 3
Other Vascular Conditions
- Peripheral arterial disease: Aspirin or clopidogrel recommended as antiplatelet prophylaxis 1
- Atrial fibrillation: Aspirin indicated for intermediate-risk patients or high-risk patients who cannot take warfarin 1
- Post-coronary bypass surgery: Aspirin reduces graft occlusion 1, 2
- Following percutaneous coronary intervention with stenting: Aspirin combined with P2Y12 inhibitor 5
Optimal Dosing Strategy
For long-term prevention in high-risk patients (≥3% annual vascular event risk), aspirin 75-100 mg daily is recommended. 1 This dosing minimizes gastrointestinal toxicity while maintaining efficacy.
For acute situations requiring immediate antithrombotic effect, a loading dose of 160-300 mg should be administered to ensure rapid and complete inhibition of platelet aggregation. 1
Risk-Benefit Considerations
The absolute benefits of aspirin substantially outweigh bleeding risks in moderate-to-high-risk settings (annual vascular event risk ≥1.5-3%). 1 However, aspirin is NOT recommended for routine primary prevention in low-risk individuals without established cardiovascular disease, as modest cardiovascular benefits may be offset by increased bleeding complications. 1
Major Bleeding Risk
Aspirin increases major bleeding, particularly gastrointestinal bleeding, with risk increasing at higher doses. When combined with clopidogrel in acute coronary syndromes, major bleeding occurs in 3.7% versus 2.7% with aspirin alone. 1
Clinical Pitfalls to Avoid
Do not use high-dose aspirin (>325 mg daily) for chronic prevention - there is no evidence of superior efficacy compared to low doses (75-100 mg), and GI toxicity increases substantially. 1, 2
Enteric-coated preparations may have inadequate bioavailability at low doses, particularly in heavier patients, potentially resulting in insufficient platelet inhibition. 2
NSAIDs (particularly ibuprofen) can interfere with aspirin's antiplatelet effects through pharmacodynamic interactions. If NSAIDs are required, selective COX-2 inhibitors may be preferable. 1
Alternative Antiplatelet Agents
For patients with aspirin allergy or contraindications, clopidogrel 75 mg daily is a reasonable alternative across most cardiovascular indications. 4, 1 In acute coronary syndromes without ST-elevation, dual antiplatelet therapy with aspirin plus clopidogrel (or ticagrelor/prasugrel) reduces cardiovascular death, MI, or stroke by 20% compared to aspirin alone. 1, 5